Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosetti

Showing results (371-380 of 386) with videos related to

Pageof 39
Sort By:
Scientific Reports|October 31, 2019
Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus StratificationDaniel Toro-Domínguez, Raúl Lopez-Domínguez, Adrián García Moreno, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|September 25, 2023
Analysis of annual distributions of hemoglobin A<sub>2</sub> values as a method to test for HbA<sub>2</sub> standardizationMatteo Vidali, Renata Paleari, Ferruccio Ceriotti, et al.
Frontiers in Immunology|June 18, 2026
Gene expression profiling of dendritic cell tolerance dysfunction in women with systemic lupus erythematosusAna Laura Hernández-Ledesma, Evelia Lorena Coss-Navarrete, Sofia Salazar-Magaña, et al.
PLOS Digital Health|January 23, 2025
Quality of life disparities among Mexican people with systemic lupus erythematosusAna Laura Hernández-Ledesma, Domingo Martínez, Elizabeth Fajardo-Brigido, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2018
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III TrialsCesare Gridelli, Alessandro Morabito, Luigi Cavanna, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trialsAlessandro Morabito, Maria Carmela Piccirillo, Paolo Maione, et al.
Cell Reports|December 12, 2025
The transcription factor Helios restrains the anti-tumor capacity of CD8<sup>+</sup> T cellsRosa M Rubio, Gerardo Suárez-Rojas, Adrián Albarrán-Godínez, et al.
Neurosurgical Review|March 27, 2025
Clinical outcomes and hemorrhagic or thromboembolic risks in decompressive craniectomy for patients taking antiplatelet or anticoagulant therapyAlba Scerrati, Giovanni Scanferla, Lorenzo Sgarbanti, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 28, 2022
Down-Regulation-Resistant STAT4 Risk Haplotype Contributes to Lupus Nephritis Through CD4+ T Cell Interferon-γ ProductionIris K Madera-Salcedo, Ada L Ramírez-Sánchez, Noé Rodríguez-Rodríguez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 TrialMaria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, et al.
Pageof 39

Showing results (371-380 of 386) with videos related to

Sort By:
Pageof 39
Scientific Reports|October 31, 2019
Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus StratificationDaniel Toro-Domínguez, Raúl Lopez-Domínguez, Adrián García Moreno, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|September 25, 2023
Analysis of annual distributions of hemoglobin A<sub>2</sub> values as a method to test for HbA<sub>2</sub> standardizationMatteo Vidali, Renata Paleari, Ferruccio Ceriotti, et al.
Frontiers in Immunology|June 18, 2026
Gene expression profiling of dendritic cell tolerance dysfunction in women with systemic lupus erythematosusAna Laura Hernández-Ledesma, Evelia Lorena Coss-Navarrete, Sofia Salazar-Magaña, et al.
PLOS Digital Health|January 23, 2025
Quality of life disparities among Mexican people with systemic lupus erythematosusAna Laura Hernández-Ledesma, Domingo Martínez, Elizabeth Fajardo-Brigido, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2018
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III TrialsCesare Gridelli, Alessandro Morabito, Luigi Cavanna, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trialsAlessandro Morabito, Maria Carmela Piccirillo, Paolo Maione, et al.
Cell Reports|December 12, 2025
The transcription factor Helios restrains the anti-tumor capacity of CD8<sup>+</sup> T cellsRosa M Rubio, Gerardo Suárez-Rojas, Adrián Albarrán-Godínez, et al.
Neurosurgical Review|March 27, 2025
Clinical outcomes and hemorrhagic or thromboembolic risks in decompressive craniectomy for patients taking antiplatelet or anticoagulant therapyAlba Scerrati, Giovanni Scanferla, Lorenzo Sgarbanti, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 28, 2022
Down-Regulation-Resistant STAT4 Risk Haplotype Contributes to Lupus Nephritis Through CD4+ T Cell Interferon-γ ProductionIris K Madera-Salcedo, Ada L Ramírez-Sánchez, Noé Rodríguez-Rodríguez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 TrialMaria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, et al.
Pageof 39